Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Inc.

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Biogen today and set a price target of $214.00. Matteis covers the Healthcare secto...

Stifel Nicolaus Keeps Their Buy Rating on Biogen (BIIB)

Wedbush analyst Laura Chico maintained a Hold rating on Biogen today and set a price target of $191.00. According to TipRanks, Chico is a 5-star an...

Wedbush Keeps Their Hold Rating on Biogen (BIIB)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Gossamer Bio (GOSS) and Biogen (BIIB). Gossamer Bio (GOSS) In a r...

Analysts Conflicted on These Healthcare Names: Gossamer Bio (GOSS) and Biogen (BIIB)

Biogen ( ($BIIB) ) just unveiled an update. On March 31, 2026, Biogen signed a merger agreement to acquire Apellis Pharmaceuticals via a tender off...

Biogen to Acquire Apellis, Expanding Ophthalmology Portfolio

The latest stock market stories for Tuesday are ready to go in the daily wrap-up.


Morning News Wrap-Up 3/31/26: Today’s Biggest Stock Market Stories!

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB) and Kezar Life Sciences (KZR). Bioge...

Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Kezar Life Sciences (KZR)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Definitive Healthcare Corp (DH) and Biogen (BIIB). Definitive Hea...

Analysts Offer Insights on Healthcare Companies: Definitive Healthcare Corp (DH) and Biogen (BIIB)

Biogen Inc. ($BIIB) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) has launched a Phase 3 trial called “A Phase 3 Study Wi...

Biogen Targets Pediatric MS Growth With New Phase 3 Fumarate Study

Biogen Inc. ($BIIB) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) has completed a Phase 1 study titled “A Phase 1, Open-L...

Biogen’s BIIB080 Imaging Study Completes, Marking Quiet but Key Step in Alzheimer’s Pipeline

Oppenheimer analyst Jay Olson maintained a Buy rating on Biogen today and set a price target of $250.00. According to TipRanks, Olson is a 5-star a...

Oppenheimer Reaffirms Their Buy Rating on Biogen (BIIB)

Biogen ( ($BIIB) ) has issued an update. On March 11, 2026, Biogen Inc. announced that its Chief Legal Officer, Susan H. Alexander, will leave the ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BIIB	$179.90	0.00%	1.29M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BIIB	$179.90	0%	1.29M
3
4
5
6

BIIB

BIIB

Get Biogen Inc. Data in Excel

Get Biogen Inc. Data in Excel